---
title: "Zepbound vs liraglutide for weight loss | HealthRX.com"
description: "Tirzepatide 15 mg led to 20.9% mean weight loss and liraglutide 3 mg to 7.4% in separate trials. Get weekly and daily dosing plus boxed warning details."
url: https://healthrx.com/compare-glp-1/zepbound-vs-liraglutide-generic--efficacy
publisher: HealthRX.com
---


HealthRX.com

Zepbound led liraglutide in separate trials

28% Nausea rate on Zepbound 15 mg, versus placebo Source: dailymed.nlm.nih.gov

[Print or save as PDF](https://healthrx.com/printables/compare-glp-1/zepbound-vs-liraglutide-generic--efficacy?print=1)

Key numbers

- 20.9% Mean weight loss at 72 weeks with tirzepatide 15 mg in separate trials of adults without diabetes Source: [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35658024/), as cited Nov 7, 2026
- -7.4% Mean body-weight change with liraglutide in the Saxenda label, versus placebo Source: [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b11f6ac-4c27-4748-9e65-22d4cf3adfb4), as cited Nov 7, 2026
- 28% Nausea rate on Zepbound 15 mg, versus placebo Source: [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b), as cited Nov 7, 2026

From the public record

Zepbound and liraglutide: how often reports say it fell short

Of 36,730 liraglutide reports, 1,870 (5.1%) say it did not work or worked less than expected, compared with 6,217 of 80,835 (7.7%) for Zepbound. Therapeutic product effect incomplete is named 219 times for liraglutide and 56 for Zepbound.

Zepbound and liraglutide: how often reports say it fell short: the figures

| Measure | Value | Note |
| --- | --- | --- |
| Reports naming a lack-of-effect term, Zepbound | 6,217 (7.7%) | of 80,835 reports |
| Reports naming a lack-of-effect term, liraglutide | 1,870 (5.1%) | of 36,730 reports |
| Drug ineffective | Zepbound 5,552, liraglutide 1,329 | reports for Zepbound, then for liraglutide |
| Therapeutic product effect incomplete | Zepbound 56, liraglutide 219 | reports for Zepbound, then for liraglutide |
| Treatment failure | Zepbound 216, liraglutide 29 | reports for Zepbound, then for liraglutide |
| Therapeutic product effect decreased | Zepbound 118, liraglutide 41 | reports for Zepbound, then for liraglutide |

Source: [FDA Adverse Event Reporting System (FAERS) via openFDA](https://open.fda.gov/data/faers/), data as of Oct 28, 2026

How this was calculated

The FAERS database was searched for each medicine's reports naming any of 16 terms for a missing, reduced or delayed effect. Reports are voluntary and unverified complaints, and the two medicines differ in who uses them and for how long.

Scope: FAERS reports for Zepbound and for liraglutide naming any of 16 lack-of-effect terms, to 2026-10-28

HealthRX.com quick answer. Zepbound (tirzepatide) produced more weight loss than liraglutide 3 mg in separate trials of adults without diabetes: a mean 20.9% with tirzepatide 15 mg over 72 weeks [1], versus 7.4% (8.4 kg against 2.8 kg on placebo) with liraglutide 3 mg over 56 weeks [2][4]. Placebo groups lost 3.1% and 3.0%. No trial compared the two drugs directly, so the size of the true difference is not known.

At a glance

- Highest-dose result, tirzepatide / 20.9% mean weight loss at 72 weeks vs 3.1% placebo, SURMOUNT-1 (N=2,539) [1]
- Highest-dose result, [liraglutide](https://healthrx.com/liraglutide-generic) / 7.4% mean loss at 56 weeks vs 3.0% placebo in the [Saxenda](https://healthrx.com/saxenda) label (8.4 kg vs 2.8 kg in the paper), SCALE Obesity (N=3,731) [2][4]
- Injection schedule / Tirzepatide once weekly; liraglutide once daily [3][4]
- Weight-management dose / Tirzepatide 5, 10 or 15 mg weekly; liraglutide 3 mg daily [3][4]
- Direct comparison trial / None; tirzepatide's head-to-head obesity trial was against semaglutide [5]
- Approved populations / Zepbound: adults only [3]; Saxenda: adults and children 12 and older above 60 kg [4]
- Boxed warning / Both: rodent thyroid C-cell tumors; contraindicated with MTC or MEN 2 history [3][4]
- Combining the two / Both labels say not to use with another GLP-1 receptor agonist [3][4]

## Is there a direct comparison?

The nearest head-to-head for tirzepatide in obesity was against semaglutide, not liraglutide. SURMOUNT-5 randomized 751 adults with obesity and no diabetes to maximum tolerated tirzepatide or semaglutide for 72 weeks: weight changed -20.2% versus -13.7% [5]. Liraglutide was not part of that trial.

## What Zepbound did in SURMOUNT-1

SURMOUNT-1 enrolled 2,539 adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related complication, and without diabetes. Mean baseline weight was 104.8 kg, treatment lasted 72 weeks, and results were calculated with a treatment-regimen estimand that counts people regardless of whether they stopped the drug [1].

Mean weight change at week 72 [1]:

- Tirzepatide 5 mg: -15.0%
- Tirzepatide 10 mg: -19.5%
- Tirzepatide 15 mg: -20.9%
- Placebo: -3.1%

All three doses beat placebo, P<0.001 [1]. Loss of 5% or more occurred in 85%, 89% and 91% of people on 5, 10 and 15 mg versus 35% on placebo [1]. The Zepbound label reports loss of 20% or more in 30.0%, 50.1% and 56.7% versus 3.1% on placebo [3].

## What liraglutide 3 mg did in its key trial

The Saxenda label's Study 1, the SCALE Obesity and [Prediabetes](https://healthrx.com/conditions-prediabetes/diagnosis-algorithm) trial, ran 56 weeks in 3,731 adults with a BMI of 30 or higher, or 27 or higher with dyslipidemia or hypertension, and no [type 2 diabetes](https://healthrx.com/conditions-type-2-diabetes/diagnosis-algorithm). Participants received liraglutide 3 mg daily (n=2,487) or placebo (n=1,244) plus lifestyle counseling, with a mean baseline weight of 106.2 kg [2].

At week 56, the paper reported mean weight loss of 8.4 kg with liraglutide 3 mg versus 2.8 kg with placebo, a difference of 5.6 kg (last observation carried forward) [2]. The Saxenda label, using multiple imputation, reports -7.4% versus -3.0% of body weight, with 62.3% versus 34.4% losing 5% or more [4].

The Saxenda label says to reassess adults at 16 weeks and to discontinue if less than 4% of baseline body weight has been lost [4].

## How the two numbers line up

The gap is wide: 20.9% on [tirzepatide](https://healthrx.com/products/tirzepatide) 15 mg against 7.4% on liraglutide 3 mg. These are separate trials that differed in length (72 versus 56 weeks), populations and statistical method, so the figures suggest greater weight loss with tirzepatide but cannot show how much more weight people would lose with it than with liraglutide in a direct comparison [1][2][4].

What people on Reddit report

Accounts from people comparing liraglutide weight loss with Zepbound or tirzepatide, mostly after switching drugs. Results vary widely between individuals.

justfacit · liraglutide

As someone who went from liraglutide to Zepbound, and also has a lot of inflammation, I will tell you that the Saxenda did not help appreciably.

Switched from liraglutide to Zepbound and says the liraglutide version did little for inflammation.

[Read the source discussion](https://www.reddit.com/r/liraglutide/comments/1qotn28/considering_the_switch_from_zepbound_to/)

Ginger_Libra · PMOSonGLP

I've been on both. The daily shots didn't bother me. I only lost 20 or so pounds on it though. I lost 60lbs on Mounjaro.

Tried both drugs and reports much larger weight loss on tirzepatide than on liraglutide.

[Read the source discussion](https://www.reddit.com/r/PMOSonGLP/comments/1nq9js5/liraglutide_victoza_cheaper_than_zepbound/)

chiieddy · Zepbound

It's effective for those it works for. Some people actually respond better on it than tirzepatide. Holistically, it's less effective than Zepbound or Wegovy.

Says liraglutide works for some people, sometimes better than tirzepatide, but is less effective overall.

[Read the source discussion](https://www.reddit.com/r/Zepbound/comments/1n2nqv0/is_liraglutide_effective_just_saw_an_article_that/)

Tom_Michel · liraglutide

In clinical trials, on average, folks on liraglutide lose less weight overall than those on semaglutide and tirzepatide, but an average is just that. Some folks lose more and some lose less, so I'm playing the odds.

Liraglutide user who accepts that trial averages are lower but expects individual results to vary.

[Read the source discussion](https://www.reddit.com/r/liraglutide/comments/1hzrpbv/advice_needed_switching_from_zepbound/)

Questions worth asking

Choose the questions you want to keep Has the weight loss difference between liraglutide and Zepbound been confirmed in a head-to-head trial? What weight loss should I realistically expect on liraglutide at the weight-management dose? How does a daily liraglutide schedule compare with a weekly Zepbound injection for my routine? Could my side effects differ between liraglutide and Zepbound? What early monitoring would my prescriber plan if I start liraglutide?

## The same comparison in people with type 2 diabetes

SURMOUNT-2 studied 938 adults with a BMI of 27 or higher and type 2 diabetes for 72 weeks. Weight change was -12.8% on tirzepatide 10 mg and -14.7% on 15 mg versus -3.2% on placebo, and 79.2% and 82.8% versus 32.5% lost 5% or more [3][6].

SCALE Diabetes studied 846 adults with overweight or [obesity and type 2 diabetes](https://healthrx.com/conditions-obesity/comorbidities) for 56 weeks. Mean weight loss was 6.0% with liraglutide 3 mg and 2.0% with placebo, and 54.3% versus 21.4% lost 5% or more [7].

The direction is the same in diabetes, and the absolute numbers are smaller for both drugs.

## Glycemic results and diabetes onset

Tirzepatide's head-to-head glycemic trial was against semaglutide. In SURPASS-2, 1,879 adults with type 2 diabetes on [metformin](https://healthrx.com/metformin) had HbA1c falls of 2.01, 2.24 and 2.30 points on tirzepatide 5, 10 and 15 mg versus 1.86 points on semaglutide 1 mg over 40 weeks [8].

Liraglutide has its own long-term diabetes-onset data. Over 160 weeks in 2,254 adults with prediabetes, diabetes was diagnosed in 2% of the liraglutide group versus 6% of the placebo group, with onset 2.7 times longer on liraglutide (hazard ratio 0.21); weight change at week 160 was -6.1% versus -1.9% [9].

## Side effects at the weight-management doses

Zepbound rates are from the pooled weight-management trials at 15 mg versus placebo: nausea 28% versus 8%, diarrhea 23% versus 8%, vomiting 13% versus 2%, constipation 11% versus 5%. Any gastrointestinal adverse reaction was reported by 56% versus 30%; 4.3% versus 0.5% stopped for a gastrointestinal reaction and 6.7% versus 3.4% stopped for any adverse reaction [3].

Saxenda rates are from its adult trials at 3 mg versus placebo: nausea 39.3% versus 13.8%, diarrhea 20.9% versus 9.9%, constipation 19.4% versus 8.5%, vomiting 15.7% versus 3.9%. About 68% versus 39% reported a gastrointestinal disorder, and 9.8% versus 4.3% stopped for an adverse reaction [4].

The Zepbound label states that adverse reaction rates from different clinical trials cannot be directly compared [3], so read those two lists as separate results rather than a ranking.

Both products carry a boxed warning about thyroid C-cell tumors in rodents, with human relevance unknown, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [3][4]. Both labels also state that use with another GLP-1 receptor agonist is not recommended [3][4].

## Dosing and injection schedule

The Zepbound label says to start at 2.5 mg once weekly for 4 weeks, then 5 mg, with 2.5 mg increases after at least 4 weeks on a dose. Maintenance is 5, 10 or 15 mg weekly, and 2.5 mg is an initiation dose only [3].

The Saxenda label says to start at 0.6 mg once daily for one week and raise the dose weekly to 3 mg daily from week 5. The label's recommended adult dose is 3 mg, and lower doses are for titration only [4].

## Zepbound and Saxenda approved patient groups

Zepbound is indicated for weight reduction in adults with obesity, or overweight plus at least one weight-related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity. The label lists no pediatric indication and says safety and effectiveness are not established in children [3].

Saxenda is indicated for adults with a BMI of 30 or higher, or 27 or higher with a comorbid condition, and for children 12 and older who weigh more than 60 kg and have obesity [4]. Liraglutide is also sold as Victoza for type 2 diabetes, at a maximum of 1.8 mg daily, a separate product from the 3 mg weight-management dose. FDA-approved generic liraglutide exists, including a Victoza-referenced generic approved 2024-12-23 [10].

## Weight regain after stopping tirzepatide or liraglutide

In SURMOUNT-4, 783 adults took tirzepatide for 36 weeks; the 670 who were then randomized had lost a mean 20.9%. Those who continued tirzepatide lost a further 5.5% over the next 52 weeks, while those switched to placebo regained 14.0% [11]. In the adolescent liraglutide trial, weight regain after stopping was greater with liraglutide than with placebo [12].

## Open questions about tirzepatide's GIP effect

Whether tirzepatide's added GIP receptor activity explains its larger weight effect is not established by these trials [3][5].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. Did any trial compare Zepbound and liraglutide directly?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Printable question sheet

Zepbound vs liraglutide questions for your prescriber

Bring this sheet to a prescriber or pharmacist visit when you are weighing Zepbound against liraglutide for weight management. Fill in your details, mark your questions, and track weight and side effects between visits.

[Open the fill-in sheet](https://healthrx.com/printables/compare-glp-1/zepbound-vs-liraglutide-generic--efficacy) Fill it in, print it or save it as a PDF. No sign-up.

Frequently asked questions

Does Zepbound beat liraglutide for weight loss?

In separate trials the margin is large: 20.9% mean weight loss at 72 weeks with tirzepatide 15 mg [1], versus 7.4% at 56 weeks with liraglutide 3 mg (8.4 kg against 2.8 kg on placebo) [2][4]. No single trial compared them directly.

Can Zepbound and liraglutide be used together?

No. The Zepbound label states that coadministration with any GLP-1 receptor agonist is not recommended [3], and the Saxenda label says it should not be given with other liraglutide products or any other GLP-1 receptor agonist [4].

Which one is injected less often?

Tirzepatide is injected once weekly, with maintenance doses of 5, 10 or 15 mg [3]. Liraglutide for weight management is injected once daily and titrated to 3 mg [4].

Do they cause the same side effects?

Both cause gastrointestinal effects. Nausea was reported by 28% on Zepbound 15 mg versus 8% on placebo [3], and by 39.3% on Saxenda 3 mg versus 13.8% on placebo [4]. The Zepbound label notes that rates from different trials cannot be directly compared [3].

Can children use either drug?

Saxenda is approved for children 12 and older who weigh more than 60 kg and have obesity [4]. Zepbound has no pediatric indication and its label says safety and effectiveness are not established in pediatric patients [3].

What happens to weight after stopping?

In SURMOUNT-4, people who continued tirzepatide after 36 weeks of treatment lost another 5.5%, while those switched to placebo regained 14.0% over 52 weeks [11]. In the adolescent liraglutide trial, regain after stopping was greater with liraglutide than with placebo [12].

References

Show all 16 references Hide references

1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. [Tirzepatide Once Weekly for the Treatment of Obesity](https://pubmed.ncbi.nlm.nih.gov/35658024/). N Engl J Med. 2022;387(3):205-216.
2. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. [A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management](https://pubmed.ncbi.nlm.nih.gov/26132939/). N Engl J Med. 2015;373(1):11-22.
3. U.S. National Library of Medicine, DailyMed. Zepbound injection (tirzepatide) prescribing information. [Zepbound injection (tirzepatide) label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
4. U.S. National Library of Medicine, DailyMed. Saxenda injection (liraglutide) prescribing information. [Saxenda injection (liraglutide) label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b11f6ac-4c27-4748-9e65-22d4cf3adfb4)
5. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. [Tirzepatide as Compared with Semaglutide for the Treatment of Obesity](https://pubmed.ncbi.nlm.nih.gov/40353578/). N Engl J Med. 2025;393(1):26-36.
6. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. [Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial](https://pubmed.ncbi.nlm.nih.gov/37385275/). Lancet. 2023;402(10402):613-626.
7. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. [Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial](https://pubmed.ncbi.nlm.nih.gov/26284720/). JAMA. 2015;314(7):687-99.
8. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. [Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes](https://pubmed.ncbi.nlm.nih.gov/34170647/). N Engl J Med. 2021;385(6):503-515.
9. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. [3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial](https://pubmed.ncbi.nlm.nih.gov/28237263/). Lancet. 2017;389(10077):1399-1409.
10. [U.S. Food and Drug Administration](https://api.fda.gov/drug/label.json?search=openfda.generic_name:liraglutide).
11. Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. [Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial](https://pubmed.ncbi.nlm.nih.gov/38078870/). JAMA. 2024;331(1):38-48.
12. Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. [A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity](https://pubmed.ncbi.nlm.nih.gov/32233338/). N Engl J Med. 2020;382(22):2117-2128.
13. Reddit participants. [Considering the switch from Zepbound to liraglutide (r/liraglutide)](https://www.reddit.com/r/liraglutide/comments/1qotn28/considering_the_switch_from_zepbound_to/). Accessed 2026-11-10.
14. Reddit participants. [Liraglutide (Victoza) cheaper than Zepbound? (r/PMOSonGLP)](https://www.reddit.com/r/PMOSonGLP/comments/1nq9js5/liraglutide_victoza_cheaper_than_zepbound/). Accessed 2026-11-10.
15. Reddit participants. [Is liraglutide effective? Just saw an article that a generic version was approved (r/Zepbound)](https://www.reddit.com/r/Zepbound/comments/1n2nqv0/is_liraglutide_effective_just_saw_an_article_that/). Accessed 2026-11-10.
16. Reddit participants. [Advice needed: Switching from Zepbound (r/liraglutide)](https://www.reddit.com/r/liraglutide/comments/1hzrpbv/advice_needed_switching_from_zepbound/). Accessed 2026-11-10.

Next in this cluster

Related reading

- [tirzepatide Zepbound efficacy plateau](https://healthrx.com/titration-zepbound/plateau-strategy)
- [zepbound vs liraglutide Tirzepatide vs liraglutide](https://healthrx.com/compare-glp-1/zepbound-vs-liraglutide-generic--side-effects)
- [zepbound vs liraglutide Tirzepatide vs liraglutide](https://healthrx.com/compare-glp-1/zepbound-vs-liraglutide-generic--switching)
- [zepbound vs mounjaro Zepbound vs Mounjaro](https://healthrx.com/compare-glp-1/zepbound-vs-mounjaro--cost-access)
- [zepbound vs mounjaro Zepbound vs Mounjaro: Head-to-Head Efficacy Comparison](https://healthrx.com/compare-glp-1/zepbound-vs-mounjaro--efficacy)
- [zepbound vs mounjaro Zepbound vs Mounjaro side effects](https://healthrx.com/compare-glp-1/zepbound-vs-mounjaro--side-effects)
- [zepbound vs mounjaro Zepbound vs Mounjaro: Switching Between Them](https://healthrx.com/compare-glp-1/zepbound-vs-mounjaro--switching)
- [zepbound vs ozempic Zepbound vs Ozempic](https://healthrx.com/compare-glp-1/zepbound-vs-ozempic--cost-access)
- [zepbound vs ozempic Zepbound vs Ozempic Head-to-Head Efficacy](https://healthrx.com/compare-glp-1/zepbound-vs-ozempic--efficacy)
- [liraglutide Caffeine liraglutide interaction](https://healthrx.com/supplements-liraglutide-generic/with-caffeine)
- [mounjaro Mounjaro vs Zepbound](https://healthrx.com/glp-1/mounjaro-vs-zepbound)
- [liraglutide Liraglutide standard titration](https://healthrx.com/titration-liraglutide-generic/standard-titration)
- [liraglutide Anthem Saxenda coverage](https://healthrx.com/glp-1-questions/does-anthem-cover-saxenda)
- [liraglutide Liraglutide Life Events That Affect Dosing](https://healthrx.com/lifestyle-liraglutide-generic/life-events)

![liraglutide vs Zepbound efficacy: doctor reviewing trial results graph with patient in clinic](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/compare-glp-1/zepbound-vs-liraglutide-generic--efficacy.webp)

A clinician walking a patient through trial results shows why separate studies can't be compared directly. Full Zepbound vs liraglutide guide and sources at [healthrx.com/compare-glp-1](https://healthrx.com/compare-glp-1).
